Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blisibimod in IgA nephropathy
2014-001365-26Phase 2Terminated
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- May 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Blisibimod plus ACEI/ARB with Placebo plus ACEI/ARB (2 arms). Primary endpoint: Primary efficacy analysis. Started May 2014; status: terminated.
02
Drugs
blisibimod
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2014-001365-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001365-26.